Beyond Biotech - the podcast from Labiotech

The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at …

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. 

The company's lead asset, br…

Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs).

Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myelom…

Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). 

Diamyd is an antigen-specific immunomodulator…

Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes.  

Leukodystrophies are a gro…

Hearing loss is a huge – and growing – global challenge.

Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address…

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the…

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling.…

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhib…

Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact. 

There are few…

This week, we have a conversation about clinical trial design with Gen Li, the president and founder of Phesi, a global provider of patient-centric data analysis. 

Earlier this year, Phesi’s global an…

RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. 

The company invests in both public and private compan…

Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcript…

Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. 

Its mission is to use …

It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way.

Recently, Boehringer Ingelheim and Sosei Group Cor…

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential si…

Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable…

Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), …

After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. 

One of the biggest reasons it’s trailed behind has been the difficulty in teasin…

Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.

A new collaboration between artificial intelligence drug discovery company In…